The Idealized Lung Clearance Index: tuning in to the silent years of cystic fibrosis
Lead Research Organisation:
Imperial College London
Department Name: National Heart and Lung Institute
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
| Jane Davies (Principal Investigator) |
Publications
Hine C
(2022)
A systematic review of lung clearance index in non-cystic fibrosis, non-primary ciliary dyskinesia bronchiectasis.
in Respiratory medicine
Robinson PD
(2022)
Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials.
in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Sandhu D
(2023)
Computed cardiopulmonography and the idealized lung clearance index, iLCI 2.5 , in early-stage cystic fibrosis
in Journal of Applied Physiology
Saunders C
(2020)
Integrating the multiple breath washout test into international multicentre trials.
in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Short C
(2022)
A Short extension to multiple breath washout provides additional signal of distal airway disease in people with CF: A pilot study
in Journal of Cystic Fibrosis
Short C
(2020)
Utility of lung clearance index in CF: What we know, what we don't know and musings on how to bridge the gap.
in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Short C
(2020)
Horses for courses: Learning from functional tests of pulmonary health?
in Pediatric pulmonology
Smith N
(2022)
The Lognormal Lung: A new approach to quantifying lung inhomogeneity in COPD
in Frontiers in Physiology
| Description | Adult CF patients plus healthy controls were initially tested on the iLCI device designed for adults plus the Exhalyzer D device. A paediatric iLCI device is currently being built and will be ready to use during 2022 to investigate how the novel gas analyser can measure the paediatric population. 10 adult CF subjects (5 female) plus 14 healthy controls (7 female), age range 19-54 yrs performed both the novel iLCI test plus the standardised MBW test using the Exhalyzer D device a minimum of 2 times at 2 separate visits. Device comparison revealed significant differences in FRC measurement likely attributable to device algorithms and design differences. However, there was good inter-repeat FRC reproducibility within guideline recommendations. Additionally, in line with current literature, LCI was a sensitive indicator of disease status. |
| Exploitation Route | Further LGA validation and standardisation work is warranted. |
| Sectors | Healthcare |
| Title | Standardised lung clearance index |
| Description | sensitive measure of airways disease; increasingly adopted as an outcome measure in clinical trials. Standardisation, training, certification and quality-controlled over-reading services led by my team as the LCI Core Facility on behalf of the European CF Clinical Trials Network. |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | several novel CF treatments received license extensions into the paediatric age range based on data provided from trials using LCI as the primary outcome |
| URL | https://www.ecfs.eu/ctn/lci/lci-core-facility-definition |
| Title | Update of project The idealised LCI (i-LCI): tuning in on the 'silent years' of paediatric CF |
| Description | To determine the range and reproducibility of non-invasive indices of ventilation inhomogeneity in people with CF using a novel laser gas analyser (LGA) recently developed that aims to accurately quantify ventilation inhomogeneity to a higher degree than previously possible. The indices measured are to be compared with those measured in normal volunteers. The LGA will be compared to a validated multiple breath washout (MBW) test which also measures ventilation inhomogeneity in the lungs Adult CF patients plus healthy controls were initially tested on the iLCI device designed for adults plus the Exhalyzer D device. A paediatric iLCI device is currently being built and will be ready to use during 2022 to investigate how the novel gas analyser can measure the paediatric population. 10 adult CF subjects (5 female) plus 14 healthy controls (7 female), age range 19-54 yrs performed both the novel iLCI test plus the standardised MBW test using the Exhalyzer D device a minimum of 2 times at 2 separate visits. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | Device comparison revealed significant differences in FRC measurement likely attributable to device algorithms and design differences. However, there was good inter-repeat FRC reproducibility within guideline recommendations. Additionally, in line with current literature, LCI was a sensitive indicator of disease status. Further LGA validation and standardisation work is warranted. |
| Description | European Lung Clearance Index Core Facility |
| Organisation | European Cystic Fibrosis Society (ECFS) |
| Country | Denmark |
| Sector | Charity/Non Profit |
| PI Contribution | Direct the LCI Core Facility Train, certify and standardise operators across European CF clinical trial sites; over-reading and quality assurance service to clinical trial sponsors |
| Collaborator Contribution | Close partnership with counterparts in N. America and Australasia to provide global services |
| Impact | multiple papers listed in publications |
| Start Year | 2021 |
| Description | European Lung Clearance Index Core Facility |
| Organisation | The Hospital for Sick Children (SickKids) |
| Department | MICe Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Direct the LCI Core Facility Train, certify and standardise operators across European CF clinical trial sites; over-reading and quality assurance service to clinical trial sponsors |
| Collaborator Contribution | Close partnership with counterparts in N. America and Australasia to provide global services |
| Impact | multiple papers listed in publications |
| Start Year | 2021 |
| Description | Conference talk/poster |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference presentation/poster at Physiology conference. Abstract: Utilising Computational Methods to Determine an Idealised Lung Clearance Index. Sandhu D, Redmond J, Smith NMJ, Short C, Saunders CJ, Couper JH, Fullerton CJ, Richmond G, Talbot NP, Davies JC, Ritchie GAD, Robbins PA |
| Year(s) Of Engagement Activity | 2022 |
| Description | Presentation at the North American CF Conference 2021 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chris Short presented at the NACF Conference 2021 at workshop 'Multiple Breath Washout: Ready for Prime Time?' The presentation reached a wide target audience and generated further questions and discussion. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Symposium honouring Bonnie Ramsey |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Professor Jane Davies gave a symposium of her career research to date in honour of Bonnie Ramsey. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Talk at CF Clinical Trials Conference 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Professor Jane Davies presented at the Cystic Fibrosis CF Trials Conference in 2022. The title of her talk was Trials in infants and pre-school children. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Talk at Royal Society of Medicine Paediatric Respiratory and ENT Symposium 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Professor Jane Davies presented at the Royal Society of Medicine Paediatric Respiratory and ENT Symposium 2022. The title of her talk was 'Cystic fibrosis: What's new?' |
| Year(s) Of Engagement Activity | 2022 |